It seems especially appropriate that we recognize these two leaders in the field of radiation oncology and former leaders of ASTRO as part of our 50th anniversary Louis Harrison, chairman of the ASTRO Board of Directors and an oncologist said at the Beth Israel Medical Center in New York City read full text . Both leaders have role models for me role models for me and I’m going to great personal pride in a position to take her hand over their medals. Rose is the technical and associate director of Valley Radiotherapy Associates Medical Group, Medical Director of the Center for Radiation Therapy of Beverly Hills, and Chief Technology Officer of Vantage Oncology, He graduated from Harvard Medical School in Boston and has both his internship and residency in internal medicine at Beth Israel Hospital in Boston. Rose finished his residence in radiation at the Joint Center for Radiation Therapy in Boston and a scholarship to the the Royal Marsden Hospital in Sutton, He has also served in several callings, including as a lecturer and assistant professor of radiation oncology at Harvard Medical School as an exceptional clinical associate professor of radiation oncology at the University of Southern California in Los Angeles. Rose is a member of several professional societies, including the American Society of Clinical Oncology, the Radiation Research Society and the California Radiation Oncology Society. He is Vice – Chairman of the Quality Research in Radiation Oncology Fellowship of the American College of Radiology. He was named a Fellow of the American College of Radiology in 1993, a fellow of ASTRO in 2006 and was as president of the Southern California Radiation Oncology Society serves, CARROS and ASTRO. Tepper is the Hector MacLean Distinguished Professor of Cancer Research and professor of radiation oncology at the University of North Carolina School of Medicine, where he was chairman for nearly 20 years, he received his bachelor’s degree from MIT, his medical degree from the Washington University School of medicine in St. Louis and completed his internship in internal medicine at Presbyterian-St. Luke’s Hospital in Chicago. Tepper has his residency and fellowship in Radiation Oncology at Massachusetts General Hospital in Boston. He is a member of the American Society of Clinical Oncology, the North Carolina Medical Society, the Radiation Research Society and the American Association for Cancer Research, along with several other professional societies. He was named a Fellow of the ACR in 1996 and fellow of ASTRO 2006th Tepper served as ASTRO president from 2002-2003 and served as Chairman of the Board of Directors. He is currently serving on the ASCO Board of Directors. Tepper main research interests include gastrointestinal tumor, combined. Modality therapy and soft tissue sarcoma He is editor of the seminar in Radiation Oncology, editor of two books, director of the UNC GI SPORE grant and co-chair of the GI Steering Committee of the NCI.
Mike Stowe, SpePharm UK Ltd. Managing Director added: We all feel very positive about the launch in the UK Loramyc the first feedback from experts is a real need for this product due to the lack of optimal efficacy and compliance issues with currently available products. Although the guidelines recommend the first line use of a topical buccal treatment for OPC, in many cases forced forced to systemic drugs with the attendant risks of generating both resistance and potentially serious drug interactions immediately. We believe Loramyc. The only topical, once daily, effective treatment for OPC in this important group of immunocompromised patients .
University of Kentucky 102 Mathews Bldg.